Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecopipam DDI Study in Healthy Subjects
NCT04764851Phase 1Terminated
- Sponsor
- Emalex Biosciences
- Start
- Feb 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ecopipam in Tourette syndrome (TS) (3 cohorts), sponsored by Emalex Biosciences. Primary endpoints: Cmax of dextromethorphan (and its dextrorphan metabolite), Cmax of IV midazolam (and its 1'-hydroxymidazolam metabolite) and 19 more. Started Feb 2021; status: terminated.
02
Drugs
ecopipam
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT04764851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04764851.